Is the dream over for stem-cell therapy for HF?
The DREAM-HF trial failed to meet its primary endpoint, but the therapy was associated with better outcomes, researchers report
Mesenchymal precursor cell therapy did not meet its primary endpoint of reducing heart failure hospitalisations in a phase III trial, but secondary outcomes do suggest some benefits, researchers report.
Professor Emerson Perin of Texas Heart Institute, US told delegates at the American Heart Association Scientific Sessions 2021 virtual meeting that mesenchymal precursor cells (MPCs) may decrease cardiac inflammation, reduce heart muscle death, induce a microvascular network in heart muscle, and reverse endothelial dysfunction.
